OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Outlook Therapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1] Summary by Relevant Sections Class Action Complaint - The class action complaint was filed on November 3, 2023, covering a Class Period from December 29, 2022, to August 29, 2023 [1] - Allegations include that the defendants made materially false and misleading statements regarding the company's business and operations [2] Specific Allegations - Lack of substantial evidence supporting ONS-5010 as a treatment for wet AMD [2] - Deficiencies in chemistry manufacturing and controls (CMC) and other manufacturing issues for ONS-5010 that were unresolved at the time of BLA resubmission to the FDA [2] - Unlikelihood of FDA approval for ONS-5010 BLA in its current form due to the aforementioned issues [2] - Overstated regulatory and commercial prospects for ONS-5010 [2] - Public statements made by the company were materially false and misleading throughout the relevant period [2]